콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

P4050000

Pyrazinamide

European Pharmacopoeia (EP) Reference Standard

동의어(들):

Pyrazinecarboxamide, Pyrazinamide, Pyrazinoic acid amide

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C5H5N3O
CAS Number:
Molecular Weight:
123.11
Beilstein:
112306
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

pyrazinamide

제조업체/상표

EDQM

mp

189-191 °C (lit.)

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

2-8°C

SMILES string

NC(=O)c1cnccn1

InChI

1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)

InChI key

IPEHBUMCGVEMRF-UHFFFAOYSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Pyrazinamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

죄송합니다. 지금은 이 제품에 대한 COA이(가) 온라인에서 제공되지 않습니다.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

A Somoskovi et al.
Respiratory research, 2(3), 164-168 (2001-11-01)
Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an
L Gwaza et al.
Clinical pharmacology and therapeutics, 96(5), 580-588 (2014-07-06)
Approval of generic medicines is based on bioequivalence with the innovator product, but it is not unusual for generics to be interchanged with each other. This study investigated the differences in bioavailability between World Health Organization-prequalified antituberculosis generics by means
D A Mitchison et al.
Tuberculosis (Edinburgh, Scotland), 90(3), 177-181 (2010-04-13)
While we wait for improved new anti-tuberculosis drugs, the main aim for improving current treatment should be to optimize the use of the two current drugs, rifampicin and the pro-drug pyrazinamide, which are responsible to a similar extent for the
Tawanda Gumbo et al.
The Journal of antimicrobial chemotherapy, 69(9), 2420-2425 (2014-05-14)
To identify the pyrazinamide MIC above which standard combination therapy fails. MICs of pyrazinamide were determined for Mycobacterium tuberculosis isolates, cultured from 58 patients in a previous randomized clinical trial in Cape Town, South Africa. The MICs were determined using
X Gonzalo et al.
The Journal of antimicrobial chemotherapy, 69(11), 3001-3005 (2014-06-26)
Pyrazinamide is a key first-line tuberculosis drug. Reliable drug susceptibility testing (DST) data are of clinical importance, but in vitro testing is challenging since the activity of pyrazinamide is pH sensitive. The BACTEC MGIT 960 is considered the principal reference

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.